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Simple Summary: The loss of skeletal muscle mass is known to be associated with poor treatment
outcome, treatment-related toxicity, and high mortality. The association between loss of skeletal
muscle mass and the response to treatment is not well-defined yet. In this study, we evaluated the
impact of loss of skeletal muscle mass on responsiveness to neoadjuvant chemotherapy in breast
cancer. The prediction of response to neoadjuvant chemotherapy could be helpful to guide the
treatment direction.
Abstract: There are no means to predict patient response to neoadjuvant chemotherapy (NAC); the
impact of skeletal muscle loss on the response to NAC remains undefined. We investigated the asso-
ciation between response to chemotherapy and skeletal muscle loss in breast cancer patients. Patients
diagnosed with invasive breast cancer who were treated with NAC, surgery, and radiotherapy were
analyzed. We quantified skeletal muscle loss using pre-NAC and post-NAC computed tomography
scans. The response to treatment was determined using the Response Evaluation Criteria in Solid
Tumors. We included 246 patients in this study (median follow-up, 28.85 months). The median age
was 48 years old (interquartile range 42–54) and 115 patients were less than 48 years old (46.7%).
Patients showing a complete or partial response were categorized into the responder group (208 pa-
tients); the rest were categorized into the non-responder group (38 patients). The skeletal muscle
mass cut-off value was determined using a receiver operating characteristic curve; it showed areas
under the curve of 0.732 and 0.885 for the pre-NAC and post-NAC skeletal muscle index (p < 0.001
for both), respectively. Skeletal muscle loss and cancer stage were significantly associated with poor
response to NAC in locally advanced breast cancer patients. Accurately measuring muscle loss to
guide treatment and delaying muscle loss through various interventions would help enhance the
response to NAC and improve clinical outcomes.
Keywords: breast cancer; skeletal muscle loss; treatment-induced cachexia
1. Introduction
Neoadjuvant chemotherapy (NAC) for breast cancer has a high clinical response rate.
In some cases, NAC facilitates the conversion of unresectable, locally advanced breast
cancer to operable cancer [1,2]. Consequently, conversion to resectable status leads to an
increase in the breast conservation rate [3,4]. Some patients undergoing NAC for breast
cancer show an insufficient response to therapy. Currently, we do not have the means to
predict whether patients will respond well to NAC or not.
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The loss of skeletal muscle mass is known to be a poor prognostic factor in patients
with malignancies. It is highly associated with chemotherapy toxicity [5,6], tumor progres-
sion [6], and mortality [7]. The impact of skeletal muscle loss on the response to treatment
remains undefined. Although there is no established standard method for skeletal muscle
quantification, computed tomography (CT) is used to measure the skeletal muscle mass.
CT images are frequently obtained for cancer patients as a part of staging and evaluating
the progress of disease during treatment.
To our knowledge, this study is the first to investigate the association between skeletal
muscle loss and responsiveness to NAC. In this study, we analyzed the association between
skeletal muscle loss and the response to NAC to evaluate the impact of skeletal muscle
loss in patients receiving NAC for locally advanced breast cancer. Being able to predict the
response to NAC would help guide the treatment direction.
2. Patients and Methods
2.1. Patient Population
Patients diagnosed with breast cancer who were treated with NAC, surgery, and
radiotherapy (RT) from March 2013 to September 2019 were included and analyzed. The
chemotherapy regimen and schedule were decided at the physician’s discretion. The
clinical and laboratory data of patients were collected through electronic medical records.
We analyzed 246 patients in total. The inclusion criteria for the patients were as
follows: (1) age more than 18 years, (2) treatment with either partial mastectomy or total
mastectomy, (3) treatment with NAC and adjuvant RT, and (4) available medical records.
The exclusion criteria for patients were as follows: (1) follow-up loss, (2) inability to
measure the skeletal muscle mass, and (3) synchronous malignancies. Every patient in
this study received neoadjuvant chemotherapy, operation, and adjuvant radiotherapy. The
adjuvant radiotherapy was performed in patients with tumor stage III/IV or extensively
positive lymph node initially among the patients who underwent total mastectomy. This
study was approved by the institutional review board of Gangnam Severance Hospital
(3-2020-0509). Because the study was retrospective, the need for written informed consent
was waived.
2.2. Measurement of Body Composition and the Definition of Skeletal Muscle Loss
CT was used to measure body composition. Generally, skeletal muscle mass is evalu-
ated at the level of the third lumbar vertebra (L3) on abdominal/pelvic CT scans. Most of
the patients in our study underwent abdominal/pelvic CT for the assessment of metastatic
lesions. However, a few patients did not undergo abdominal/pelvic CT. Some recent
studies have evaluated the skeletal muscle index (SMI) at the level of the fourth thoracic
vertebra (T4) on chest CT scans [8,9]. Similarly, we assessed the SMI at the upper border of
T4 (Figure 1).
We estimated the SMI using CT scans taken within 3 months of diagnosis and those
taken for radiotherapy (RT) simulations. CT was performed before the initiation of NAC
and after the completion of NAC; thus, pre-NAC and post-NAC CT scans were obtained for
each patient. We used the MIM Vista software (MIM corp., Version 6.6.14., Cleveland, OH,
USA) to delineate the body composition based on Hounsfield units (HUs). The following
HU threshold was applied for skeletal muscle delineation: from −29 to +150. The cross-
sectional volumes obtained from the MIM software at the T4 level were divided by the
thickness of the axial slice and defined as the cross-sectional areas. The SMI was calculated
by dividing the cross-sectional areas by the height of the patients.
Similar to skeletal muscle, subcutaneous adipose tissue composition was delineated
based on HUs: −190 to −30 HU. The subcutaneous adipose tissue index was determined
by dividing the cross sectional volume of subcutaneous adipose tissue at the T4 level with
thickness of axial slice.




Figure 1. Computed tomography images of patients with skeletal muscle loss (upper) and without 
skeletal muscle loss (lower). skeletal muscle index of upper image: 4.88, skeletal muscle index of 
lower image: 9.83 
We estimated the SMI using CT scans taken within 3 months of diagnosis and those 
taken for radiotherapy (RT) simulations. CT was performed before the initiation of NAC 
and after the completion of NAC; thus, pre-NAC and post-NAC CT scans were obtained 
for each patient. We used the MIM Vista software (MIM corp., Version 6.6.14., Cleveland, 
OH, USA) to delineate the body composition based on Hounsfield units (HUs). The fol-
lowing HU threshold was applied for skeletal muscle delineation: from −29 to +150. The 
cross-sectional volumes obtained from the MIM software at the T4 level were divided by 
the thickness of the axial slice and defined as the cross-sectional areas. The SMI was cal-
culated by dividing the cross-sectional areas by the height of the patients. 
Similar to skeletal muscle, subcutaneous adipose tissue composition was delineated 
based on HUs: −190 to −30 HU. The subcutaneous adipose tissue index was determined 
by dividing the cross sectional volume of subcutaneous adipose tissue at the T4 level with 
thickness of axial slice. 
2.3. Statistical Analysis 
We aimed to investigate the association between skeletal muscle loss status and re-
sponsiveness to treatment. Responsiveness to treatment was evaluated according to the 
Response Evaluation Criteria in Solid Tumors [10]. The treatment response was evaluated 
based on the image study of the patients. Magnetic resonance imaging (MRI) was used 
for the evaluation before and after NAC. Patients showing either a complete response or 
partial response in the MRI performed after NAC were classified into the responder 
group, while patients with either stable disease or progressive disease were categorized 
into the non-responder group. 
For categorical data, Fisher’s exact test was used for comparison between the groups. 
The Mann–Whitney U-test was used to compare continuous variables between the 
groups. The logistic regression method was used to determine the association between the 
Figure 1. Computed tomography images of patients with skeletal muscle loss (upper) and without
skeletal muscle loss (lower). skeletal muscle index of upper image: 4.88, skeletal muscle index of
lower i age: 9.83.
2.3. Statistical Analysis
We aimed to investigate the a sociation between skele al muscle l ss status and
responsiveness to treatment. Responsiveness to treatment was ev luat d according to the
Response Evaluation Criteria in Solid Tumors [10]. The treatment response was evaluated
based on the image study of the patients. Magnetic resonance imaging (MRI) was used
for the evaluation before and after NAC. Patients showing either a complete response or
partial response in the MRI performed after NAC were classified into the responder group,
while patients with either stable disease or progressive disease were categorized into the
non-responder group.
For categorical data, Fisher’s exact test was used for comparison between the groups.
The Mann–Whitney U-test was used to compare continuous variables between the groups.
T e logistic regre sion method was used to determine the association between the variables
and the response to NAC. A p-value < 0.05 was considered statistically significant. A
multivariate a l sis was conducted among the significant variables in the univariate
analysis, with he calcul ion of haz rd ratios a d 95% confid nce interv ls. IBM SPSS
version 25.0 (SPSS, Chicago, IL, USA) was us d for analysis.
3. R sults
3.1. Patient and Tumor Characteristics
We included 246 patients with breast cancer in this study. The median follow-up
duration was 28.85 months (interquartile range [IQR], 18.20–41.10 months). The median
age was 48 years (IQR, 42–54 years). Thirty-one patients had hypertension (12.6%), and
17 patients had diabetes mellitus (6.90%). Among the entire cohort, 71 patients performed
regular ex rcise (28.9%). During the treatment, 21 patients howed w ight gain (8.5%),
while 14 patients showed weight loss (5.7%). Thirty patients had skeletal muscle loss before
NAC (12.20%), while 33 patients were stratified as having skeletal muscle loss based on
the post-NAC CT scan (Table 1). Among the 30 patients who showed skeletal muscle
loss on the pre-NAC CT scan, 18 showed skeletal muscle loss both on the pre-NAC and
post-NAC CT scans (7.3%), while 12 patients did not show skeletal muscle loss on the
post-NAC CT scan (4.9%). Fifty patients showed a transition to skeletal muscle loss status
after NAC (20.3%). Also, the body mass index (BMI) of the patients was evaluated. Eight
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patients showed underweight, with BMI less than 18.5 (3.3%), while 43 patients stratified
as overweight (17.5%).
Table 1. Patient characteristics.
Characteristics Number %
Age




















Current drinker 21 8.60%
Ex-drinker 6 2.50%
Skeletal muscle mass_pre-NAC
Skeletal muscle loss 30 12.20%
Non-skeletal muscle loss 216 87.80%
Skeletal muscle mass_post-NAC
Skeletal muscle loss 33 13.50%
Non-skeletal muscle loss 213 86.50%
Change in skeletal muscle mass
Skeletal muscle loss→ Skeletal muscle loss 18 7.30%
Skeletal muscle loss→ Non-skeletal muscle loss 12 4.90%
Non-skeletal muscle loss→ Skeletal muscle loss 15 6.10%
Non-skeletal muscle loss→ Non-skeletal muscle loss 201 81.70%
Body mass index
Underweight (<18.5) 8 3.30%
Normal (18.5–23) 128 52.00%
Overweight (23–25) 43 17.50%
Obese (≥25) 67 27.20%
Hemoglobin
Median (IQR) 13.2 (12.5–13.9)
Platelets
Median (IQR) 268 (229–312)
Albumin
Median (IQR) 4.5 (4.3–4.6)
Protein
Median (IQR) 7.4 (7.1–7.7)
Abbreviations: IQR, Interquartile range; NAC, Neoadjuvant chemotherapy.
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Tumor characteristics are presented in Table 2. The rates of estrogen receptor (ER) and
progesterone receptor (PR) positivity were 59.8% and 30.5%, respectively, and 30.9% of
patients tested positive for human epidermal growth factor receptor 2 (HER2). Sixty-one
patients had stage T3/4 tumors (24.8%), and 114 patients had stage III tumors (46.3%).
Breast-conserving surgery was performed in 129 patients (52.4%). In terms of adjuvant
treatment, 103 patients (41.9%) received a selective ER modulator, and 26 patients (10.6%)
were treated with an aromatase inhibitor. Trastuzumab-based NAC was administered to
72 patients (29.3%).






















Breast-conserving surgery 129 52.40%
Modified radical mastectomy 117 47.60%
RT modality
3D CRT 57 23.20%
IMRT 189 76.80%
Dose scheme
180 cGy per fraction 226 91.90%
200 cGy per fraction 8 3.20%


















Adriamycin based 5 2.00%
Adriamycin and taxol based 161 65.40%
Taxol based 8 3.30%
Trastuzumab based 72 29.30%






Abbreviations: IDC, Invasive ductal carcinoma; ILC, Invasive lobular carcinoma; T stage, Tumor stage; N stage,
Node stage; RT, Radiotherapy; 3D CRT, 3-dimensional conformal radiotherapy; IMRT, Intensity-modulated
radiation therapy; ER, Estrogen receptor; PR, Progesterone receptor, HER2, Human epidermal growth factor
receptor 2.
3.2. Cut-Off Value of the SMI for Skeletal Muscle Loss Group
We used the receiver operating characteristic (ROC) curve to determine the optimal
cut-off value of SMI at the T4 level as there is no established value. The SMI value of 6, both
pre-NAC and post-NAC, showed good sensitivity and specificity for responsiveness to
NAC. On the basis of the area under the ROC curve (AUC) of 0.732 (Figure 2), we identified
the pre-NAC SMI at the T4 level as a good predictor of responsiveness to NAC. Figure 3
demonstrates the ROC curve of the post-NAC SMI for predicting responsiveness to NAC;
the AUC was 0.885, indicating that it was as an excellent predictor.




Figure 2. Receiver operating characteristic curve of the skeletal muscle index at the T4 level prior 
to the initiation of neoadjuvant chemotherapy. 
 
Figure 3. Receiver operating characteristic curve of the skeletal muscle index at the T4 level after 
the completion of neoadjuvant chemotherapy. 
3.3. Predictive Value of Subcutaneous Adipose Tissue Index 
We also analyzed the subcutaneous adipose tissue index (SATI) to evaluate whether 
the SATI can predict the response to NAC. Both the pre-NAC and post-NAC SATI showed 
poor specificity and sensitivity in predicting responsiveness to NAC (Figures S1 and S2). 
The AUCs of pre-NAC and post-NAC SATI were 0.560 and 0.587, respectively, indicating 
SATI to be a poor predictive tool. 
Figure 2. Receiver operating characteristic curve of the skeletal muscle index at the T4 level prior to
the initiation of neoadjuvant chemotherapy.
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Figure 3. Receiver operating characteristic curve of the skeletal muscle index at the T4 level after the
completion of ne adjuvant emotherapy.
3.3. Predictive Value of Subcutaneous Adipose Tissue Index
We also analyzed the subc taneous adipose tissue index (SATI) to evaluate whether
the SATI can predict the response to NAC. Both the pre-NAC and post-NAC SATI showed
poor specificity and sensitivity in predicting responsiveness to NAC (Figures S1 and S2).
The AUCs of pre-NAC and post-NAC SATI were 0.560 and 0.587, respectively, indicating
SATI to be a poor predictive tool.
3.4. Comparison of Patient and Tumor Characteristics Between the Responder and
Non-Responder Groups
Among the 246 patients, 208 patients responded well to NAC, while 38 patients
showed a poor response. Most of the variables were well balanced between the responder
and non-responder groups. Skeletal muscle loss at both the pre-NAC and post-NAC were
associated with responsiveness to NAC. The non-responder group included more patients
with skeletal muscle loss (non-responder group vs. responder group: pre-NAC skeletal
muscle loss patients; 23.7% vs. 10.1%, p = 0.019, post-NAC skeletal muscle loss patients;
55.3% vs. 5.8%, p < 0.001) (Table 3). The non-responder group had more features of tumor
aggressiveness, such as advanced stage and a high Ki-67 index (responder group vs. non-
responder group: stage III, 41.8% vs. 71.10%, p = 0.003; Ki-67 index≥ 15%, 28.8% vs. 47.4%,
p = 0.001) (Table 4).
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Table 3. Comparison of patient characteristics according to the response to NAC.
Responder Group (n = 208) Non-Responder Group (n = 38)
Characteristics Number % Number % p-Value
Age
Median (IQR) 48 47
Hypertension 0.911
No 182 87.50% 33 86.80%
Yes 26 12.50% 5 13.20%
Diabetes mellitus 0.663
No 193 92.80% 36 94.70%
Yes 15 7.20% 2 5.30%
Exercise 0.706
No 147 70.70% 28 73.70%
Yes 61 29.30% 10 26.30%
Weight change 0.811
No change 179 86.00% 32 84.20%
Decrease 11 5.30% 3 7.90%
Increase 18 8.70% 3 7.90%
Smoking status 0.796
Non-smoker 204 98.10% 37 97.40%
Current smoker 3 1.50% 1 2.60%
Ex-smoker 1 0.50% 0 0.00%
Drinking status 0.896
Non-drinker 186 89.30% 33 86.80%
Current drinker 17 8.30% 4 10.50%
Ex-drinker 5 2.40% 1 2.70%
Skeletal muscle mass_pre-NAC 0.019
Skeletal muscle loss 21 10.10% 9 23.70%
Non- Skeletal muscle loss 187 89.90% 29 76.30%
Skeletal muscle mass post-NAC <0.001
Skeletal muscle loss 12 5.80% 21 55.30%
Non- Skeletal muscle loss 196 94.20% 17 44.70%
Change in skeletal muscle mass <0.001
Skeletal muscle loss→ Skeletal muscle loss 9 4.30% 9 23.70%
Skeletal muscle loss→ Non-skeletal muscle loss 12 5.80% 0 0.00%
Non-skeletal muscle loss→ Skeletal muscle loss 3 1.40% 12 31.60%
Non-skeletal muscle loss→ Non-skeletal muscle loss 184 88.50% 17 44.70%
Body mass index 0.903
Underweight 7 3.40% 1 2.60%
Normal 107 51.40% 21 55.30%
Overweight 36 17.30% 7 18.40%
Obese 58 27.90% 9 23.70%
Hemoglobin 0.922
Median (IQR) 13.2 13.4
Platelets 0.051
Median (IQR) 264.5 292.5
Albumin 0.125
Median (IQR) 4.5 4.6
Protein 0.937
Median (IQR) 7.4 7.45
Abbreviations: IQR, Interquartile range; NAC, Neoadjuvant chemotherapy.
Table 4. Comparison of tumor characteristics according to the response to neoadjuvant chemotherapy.
Responder Group (n = 208) Non-Responder Group (n = 38)
Characteristics Number % Number % p-Value
Pathology 0.001
IDC 201 96.60% 31 81.60%
ILC 2 1.00% 3 7.90%
Mucinous 2 1.00% 3 7.90%
Others 3 1.40% 1 2.60%
T stage 0.116
T1 42 20.20% 4 10.50%
T2 120 57.70% 19 50.00%
T3 26 12.50% 8 21.10%
T4 20 9.60% 7 18.40%
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Table 4. Cont.
Responder Group (n = 208) Non-Responder Group (n = 38)
Characteristics Number % Number % p-Value
N stage 0.076
N0 52 25.00% 6 15.80%
N1 87 41.80% 11 28.90%
N2 37 17.80% 12 31.60%
N3 32 15.40% 9 23.70%
Stage 0.003
I 9 4.30% 0 0.00%
II 112 53.90% 11 28.90%
III 87 41.80% 27 71.10%
Operation <0.001
Breast-conserving surgery 120 57.70% 9 23.70%
Modified radical mastectomy 88 42.30% 29 76.30%
RT modality 0.241
3D CRT 51 24.50% 6 15.80%
IMRT 157 75.50% 32 84.20%
Dose scheme 0.354
180 cGy per fraction 189 90.90% 37 97.40%
200 cGy per fraction 8 3.80% 0 0.00%
267 cGy per fraction 11 5.30% 1 2.60%
ER 0.236
Negative 87 41.80% 12 31.60%
Positive 121 58.20% 26 68.40%
PR 0.874
Negative 145 69.70% 26 68.40%
Positive 63 30.30% 12 31.60%
HER2 0.296
Negative 141 67.80% 29 76.30%
Positive 67 32.20% 9 23.70%
Ki-67 0.001
<15 92 44.20% 20 52.60%
≥15 60 28.80% 18 47.40%
Unknown 56 27.00% 0 0.00%
Chemotherapy regimen <0.001
Adriamycin based 1 0.50% 4 10.50%
Adriamycin and taxol based 138 66.30% 23 60.50%
Taxol based 5 2.40% 3 7.90%
Trastuzumab based 64 30.80% 8 21.10%
Selective estrogen receptor modulator 0.162
No 117 56.25% 26 68.40%
Yes 91 43.75% 12 31.60%
Aromatase inhibitor 0.560
No 185 88.90% 35 92.10%
Yes 23 11.10% 3 7.90%
Abbreviations: IDC, Invasive ductal carcinoma; ILC, Invasive lobular carcinoma; T stage, Tumor stage; N stage, Node stage; RT, Radiother-
apy; 3D CRT, 3-dimensional conformal radiotherapy; IMRT, Intensity-modulated radiation therapy; ER, Estrogen receptor; PR, Progesterone
receptor, HER2, Human epidermal growth factor receptor 2.
3.5. Univariate and Multivariate Analyses of the Response to Neoadjuvant Chemotherapy
In the multivariate Cox proportional hazard models, post-NAC skeletal muscle loss
was significantly associated with the response to NAC (Table 5). Pre-NAC skeletal muscle
loss could also significantly predict the response to NAC. Along with skeletal muscle loss,
advanced disease stage was associated with a significantly poorer response to NAC (hazard
ratio 0.28, 95% confidence interval 0.11–0.71, p = 0.007).
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Table 5. Univariate and multivariate analyses of the response to NAC.
Univariate Analysis Multivariate Analysis
Variables HR 95% CI p-Value HR 95% CI p-Value
Age (<48 vs. ≥48 years) 1.322 0.66–2.64 0.430
Smoking status 0.877
Non-smoker vs. current smoker 0.550 0.06–5.43 0.608
Non-smoker vs. ex-smoker NA NA NA
Drinking status 0.896
Non-drinker vs. current drinker 0.762 0.24–2.41 0.644
Non-drinker vs. ex-drinker 0.897 0.10–7.92 0.922
Pre-NAC skeletal muscle mass (Skeletal
muscle loss vs. non-skeletal muscle loss) 2.749 1.15–6.58 0.023 0.193 0.04–0.94 0.042
Post-NAC skeletal muscle mass (Skeletal
muscle loss vs. non-skeletal muscle loss) 20.074 8.45–47.69 <0.001 64.566 15.13–275.58 <0.001
Change in skeletal muscle mass † <0.001
Group 1 vs. 2 N/A N/A 0.999
Group 1 vs. 3 0.250 0.52–1.20 0.083
Group 1 vs. 4 10.824 3.79–30.90 <0.001
Body mass index 0.904
Underweight vs. Obese 1.086 0.12–9.90 0.942
Normal vs. Obese 0.739 0.32–1.72 0.483
Overweight vs. Obese 0.798 0.27–2.33 0.680
ER (negative vs. positive) 0.723 0.35–1.49 0.381
PR (negative vs. positive) 1.028 0.51–2.07 0.938
HER2 (negative vs. positive) 1.465 0.66–3.27 0.352
Ki-67 (<15 vs. ≥15) 0.725 0.35–1.48 0.377
Pathology 0.009 0.056
IDC vs. ILC 0.103 0.02–0.64 0.015 1.209 0.09–16.90 0.888
IDC vs. mucinous 0.103 0.02–0.64 0.015 0.067 0.01–0.47 0.006
IDC vs. others 0.463 0.05–4.59 0.510 0.640 0.03–12.71 0.770
T stage 0.131
T1 vs. T2 0.602 0.19–1.87 0.380
T1 vs. T3 0.310 0.09–1.13 0.076
T1 vs. T4 0.272 0.07–1.04 0.057
N stage 0.086
N0 vs. N1 0.913 0.32–2.61 0.865
N0 vs. N2 0.356 0.12–1.03 0.058
N0 vs. N3 0.410 0.13–1.26 0.120
Stage (stage I/II vs. stage III) 0.293 0.14–0.62 0.001 0.276 0.11–0.71 0.007
Abbreviations: NAC, Neoadjuvant chemotherapy; HR, Hazard ratio; CI, Confidence interval; NA, Not applicable; ER, Estrogen receptor;
PR, Progesterone receptor, HER2, Human epidermal growth factor receptor 2; IDC, Invasive ductal carcinoma; ILC, Invasive lobular
carcinoma; T stage, Tumor stage; N stage, Node stage. † Group 1: Patients with skeletal muscle loss in both pre-NAC and post-NAC, Group
2: Patients who had skeletal muscle loss in pre-NAC but changed to non-skeletal muscle loss in post-NAC, Group 3: Patients who changed
from non-skeletal muscle loss in pre-NAC to skeletal muscle loss in post-NAC, Group 4: Patients with non-skeletal muscle loss in both
pre-NAC and post-NAC.
4. Discussion
To our knowledge, this is the first study to evaluate the association between skeletal
muscle loss and the response to NAC in patients with locally advanced breast cancer.
Post-NAC skeletal muscle loss is more strongly related to responsiveness to NAC than
pre-NAC skeletal muscle loss. We also classified the adiposity value to evaluate its effect
on the response to NAC, but there was no association.
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CT-determined skeletal muscle mass is usually evaluated at the level of the L3 spine.
We used the SMI at the T4 level for easy evaluation as all patients with breast cancer
underwent chest CT before the start and after the completion of NAC. There is no defined
cut-off value for the SMI at the T4 level to evaluate skeletal muscle mass. For this reason,
the value determined by the ROC curve was set as the cut-off value in this study. Further
studies are needed to establish the optimal cut-off value of the SMI at the T4 level for
skeletal muscle loss.
In our study, skeletal muscle loss was significantly associated with the response to
NAC. There are several approaches to predicting the response to NAC. Physicians have
been trying to predict the effect of NAC using imaging tools [11,12] and biomarkers [13,14].
However, the obvious significant factors related to the response to NAC have not yet been
defined. This may be due to the diverse clinical outcomes depending on the molecular
subtypes of breast cancer [15]. We demonstrated that skeletal muscle loss is one of the
predictive markers for the response to NAC. Along with skeletal muscle loss, the clinical
stage of the cancer can predict the response to NAC. This is concordant with previous
studies showing that the clinical stage is associated with the response to NAC [16–18]. More
advanced stage or a larger tumor size are related to a poorer response to NAC, indicating
that a higher tumor burden may have a negative impact on the response to treatment.
Obesity is regarded as a poor prognostic factor for breast cancer [19,20]. Patients with
a high body mass index (BMI) have been reported to achieve fewer pathologic complete
responses after NAC [21,22]. This would indicate the significance of BMI as a predictive
factor for the response to NAC. However, there was no relation between high adiposity and
the response to NAC in this study. There can be two reasons for this. First, the assessment
of obesity differed according to studies. We assessed obesity based on CT-determined
SATI, while other studies evaluated obesity using BMI. The results could vary because
of differences in measurement methods. Another possible reason is the racial difference.
The number of people with a high BMI is lower in Asian populations than in Caucasian
populations, and the proportion of patients with obesity was much lower in Asians [23].
Our study could be inadequate to demonstrate an association between obesity and the
response to NAC as the number of patients with obesity was inadequate.
Recent studies have demonstrated that a low level of muscle mass is highly associated
with inflammation markers [24,25]. The local immune response drives muscle breakdown
and, consequently, leads to systemic inflammation and tumor growth [26]. Indicators of
inflammation were well-correlated with the response to treatment in various malignan-
cies [27,28]. One study reported that inflammation is a key factor for chemotherapy-induced
skeletal muscle loss in patients with cancer [29]. The levels of inflammatory cytokines,
such as interleukin 8, tumor necrosis factor alpha, and C-reactive protein, were increased
in patients with treatment-induced skeletal muscle loss, while no changes occurred in
patients without treatment-induced skeletal muscle loss. Thus, inflammation might play a
key role in enhancing treatment-induced skeletal muscle loss and affecting the response to
NAC. Several studies reported that skeletal muscle loss is associated with chemotherapy
toxicity [30,31]. Besides, one study reported that skeletal muscle loss is associated with
intolerance to treatment [32]. Prospective clinical trials are needed to further understand
the relation between the loss of muscle mass, inflammation, and the response to NAC as
well as the mechanisms underlying these relationships.
There are several limitations to this study. Due to the retrospective nature, the causal
relationships between the variables and skeletal muscle loss could not be determined. The
results of this study indicated that muscle wasting at the end of neoadjuvant treatment is
more associated with the response to treatment. Muscle wasting during treatment could be
influenced by tumor aggressiveness. Due to this reason, careful attention should be paid
in interpreting the results. Furthermore, data for some of the variables were unavailable.
For example, we could not evaluate inflammatory status based on the levels of C-reactive
protein, an objective marker for inflammatory status. Further, due to the short follow-up,
we could not evaluate survival parameters such as overall survival and progression-free
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survival. Lastly, the cut-off value of the SMI was not a confirmed optimal cut-off value.
Further studies are needed to determine the optimal cut-off value for CT-determined
skeletal muscle loss. Despite these limitations, this is the first study demonstrating the
relationship between chemotherapy-induced skeletal muscle loss and the response to NAC.
5. Conclusions
We observed that skeletal muscle loss, especially treatment-induced skeletal muscle
loss, is associated with the response to NAC in patients with locally advanced breast cancer.
The cancer stage is also significantly associated with a poor response to NAC. In the era of
precision medicine, an accurate measurement of muscle mass will help guide treatment to
achieve optimal clinical outcomes. Muscle-strengthening exercises, nutritional support,
and pharmacologic intervention would be helpful in delaying muscle degradation and
consequently enhancing the response to NAC in patients with breast cancer.
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